In 2023, Eli Lilly synthesized injectable retatrutide, the first triple-action agonist targeting GLP-1, GIP, and glucagon receptors, which is currently undergoing Phase 3 clinical trials
WeightWatchers, which has promoted a non-medical, points-based approach to food intake since its creation in the 1960s, has announced a strategic partnership in the UK with CheqUp, a provider of GLP-1 weight-loss medication and accompanying clinical support and health coaching
Foodthe preparation of and the eatingis still central to my family time. But as designers field more requests for focused, wellness-oriented spaces, theyre seeing GLP-1 use as a catalyst for a fundamentally different approach to the home layouts
Your telehealth consultation fee is separate from the cost of any medicine and is not affected by PBS status